SPONSOR
Jiangsu HengRui Medicine Co., Ltd.
Total Trials
7
Recruiting
7
Phases
Phase 2, Phase 3, Phase 1
Conditions studied: Primary Gout and HyperuricemiaHER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaAdvanced Solid Tumors Harboring RAS Mutations or AmplificationsGastric CancerLung CancerAdvanced KRAS G12D Mutant Solid TumorsAdvanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Primary Gout and Hyperuricemia, HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors Harboring RAS Mutations or Amplifications, Gastric Cancer.
The trial portfolio spans Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Jiangsu HengRui Medicine Co., Ltd.
How many clinical trials has Jiangsu HengRui Medicine Co., Ltd. sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Jiangsu HengRui Medicine Co., Ltd., of which 7 are actively recruiting participants. These trials cover conditions including Primary Gout and Hyperuricemia, HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors Harboring RAS Mutations or Amplifications. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Jiangsu HengRui Medicine Co., Ltd. research focus on?
Jiangsu HengRui Medicine Co., Ltd. clinical trials span Primary Gout and Hyperuricemia, HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors Harboring RAS Mutations or Amplifications, Gastric Cancer, Lung Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Jiangsu HengRui Medicine Co., Ltd. clinical trial?
To participate in a Jiangsu HengRui Medicine Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Jiangsu HengRui Medicine Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Jiangsu HengRui Medicine Co., Ltd.
NCT07362355 Phase 2
Recruiting
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Primary Gout and Hyperuricemia
NCT06123494 Phase 3
Recruiting
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT07142980 Phase 1
Recruiting
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT04342910 Phase 3
Recruiting
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Gastric Cancer
NCT07241767 Phase 2
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Lung Cancer
NCT07134998 Phase 1
Recruiting
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Advanced KRAS G12D Mutant Solid Tumors
NCT07102901 Phase 2
Recruiting
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Advanced Gastric Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology